Evaluation of Lassa antiviral compound ST-193 in a guinea pig model

Antiviral Research

Volumn 90, Issue 1, 2011, Pages 70-79

  Cashman, Kathleen A ^a   Smith, Mark A ^a   Twenhafel, Nancy A ^a   Larson, Ryan A ^b,c   Jones, Kevin F ^b   Allen, Robert D ^b   Dai, Dongcheng ^b   Chinsangaram, Jarasvech ^b   Bolken, Tove' C ^b   Hruby, Dennis E ^b   Amberg, Sean M ^b   Hensley, Lisa E ^a   Guttieri, Mary C ^a,d  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b SIGA Technologies Incorporated   (United States)

^c Takeda San Francisco   (United States)

^d BLACK AND VEATCH   (United States)

Author keywords

Arenavirus; Fusion inhibitor; Glycoprotein; Guinea pig; Lassa virus; Small molecule inhibitor

Indexed keywords

ANTIVIRUS AGENT; DRUG VEHICLE; RIBAVIRIN; ST 193; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFICACY; DYING; IN VITRO STUDY; IN VIVO STUDY; LASSA FEVER; LASSA VIRUS; MEDICAL RECORD; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; VIREMIA;

ANIMALS; ANTIVIRAL AGENTS; BODY TEMPERATURE; DISEASE MODELS, ANIMAL; FEMALE; GUINEA PIGS; INJECTIONS, INTRAPERITONEAL; LASSA FEVER; SURVIVAL ANALYSIS; VIREMIA;

ANIMALIA; ARENAVIRIDAE; ARENAVIRUS; CAVIA; LASSA VIRUS;

EID: 79953678352     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.02.012     Document Type: Article

References (69)

1. Agnihothram S.S., York J., Trahey M., Nunberg J.H. Bitopic membrane topology of the stable signal peptide in the tripartite Junín virus GP-C envelope glycoprotein complex. J. Virol. 2007, 81:4331-4337.
2. Atkin S., Anaraki S., Gothard P., Walsh A., Brown D., Gopal R., Hand J., Morgan D. The first case of Lassa fever imported from Mali to the United Kingdom, February 2009. Euro Surveill. 2009, 14(10). pii=19145.
3. Baize S., Marianneau P., Loth P., Reynard S., Journeaux A., Chevallier M., Tordo N., Deubel V., Contamin H. Early and strong immune responses are associated with control of viral replication and recovery in Lassa virus-infected cynomolgus monkeys. J. Virol. 2009, 83:5890-5903.
4. Bani-Sadr F., Carrat F., Pol S., Hor R., Rosenthal E., Goujard C., Morand P., Lunel-Fabiani F., Salmon-Ceron D., Piroth L., Pialoux G., Bentata M., Cacoub P., Perronne C. Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy. J. Acquir. Immune Defic. Syndr. 2005, 40:47-52. ANRS HC02-Ribavic Study Team.
5. Bausch D.G., Demby A.H., Coulibaly M., Kanu J., Goba A., Bah A., Condé N., Wurtzel H.L., Cavallaro K.F., Lloyd E., Baldet F.B., Cissé S.D., Fofona D., Savané I.K., Tolno R.T., Mahy B., Wagoner K.D., Ksiazek T.G., Peters C.J., Rollin P.E. Lassa fever in Guinea: I. Epidemiology of human disease and clinical observations. Vector Borne Zoonotic Dis. 2001, 1:269-281.
6. Borrow P., Oldstone M.B.A. Characterization of lymphocytic choriomeningitis virus-binding protein(s): a candidate cellular receptor for the virus. J. Virol. 1992, 66:7270-7281.
7. Bredenbeek P.J., Molenkamp R., Spaan W.J.M., Deubel V., Marianneau P., Salvato M.S., Moshkoff D., Zapata J., Tikhonov I., Patterson J., Carrion R., Ticer A., Brasky K., Lukashevich I.S. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology 2006, 345:299-304.
8. Buchmeier M.J., de la Torre J.-C., Peters C.J. Arenaviridae: the viruses and their replication. Fields Virology 2007, 1792-1827. Lippincott, Williams & Wilkins, New York. D.M. Knipe, P.M. Howley, D.E. Griffin, R.A. Lamb, M.A. Martin, B. Roizman, S.E. Straus (Eds.).
9. Burns J.W., Buchmeier M.J. Protein-protein interactions in lymphocytic choriomeningitis virus. Virology 1991, 183:620-629.
10. Carrion R., Brasky K., Mansfield K., Johnson C., Gonzales M., Ticer A., Lukashevich I., Tardif S., Patterson J. Lassa virus infection in experimentally infected marmosets: liver pathology and immunophenotypic alterations in target tissues. J. Virol. 2007, 81:6482-6490.
11. Carrion R., Patterson J.L., Johnson C., Gonzales M., Moreira C.R., Ticer A., Brasky K., Hubbard G.B., Moshkoff D., Zapata J., Salvato M.S., Lukashevich I.S. A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity. Vaccine 2007, 25:4093-4102.
12. Colman P.M., Lawrence M.C. The structural biology of type I viral membrane fusion. Nat. Rev. Mol. Cell Biol. 2003, 4:309-319.
13. Cummins D. Rats, fever and sudden deafness in Sierra Leone. Trop. Doct. 1992, 22:83-84.
14. Cummins D., McCormick J.B., Bennett D., Samba J.A., Farrar B., Machin S.J., Fisher-Hoch S.P. Acute sensorineural deafness in Lassa fever. JAMA 1990, 264:2093-2096.
15. Di Simone C., Buchmeier M.J. Kinetics and pH dependence of acid-induced structural changes in the lymphocytic choriomeningitis virus glycoprotein complex. Virology 1995, 209:3-9.
16. Drapeau C.M., Remotti D., Noto P., Capone A., Boumis E., Petrosillo N. Bone marrow toxicity in HCV genotype 5a-infected patient after peg-IFN alpha-2a and ribavirin therapy. J. Chemother. 2008, 20:648-651.
17. Enria D., Mills J.N., Flick R., Bowen M.D., Bausch D., Shieh W.J., Peters C.J. Arenavirus infections. Tropical Infectious Diseases: Principles, Pathogens & Practice 2006, 734-755. Elsevier, Philadelphia. 2nd ed. R.L. Guerrant, D.H. Walker, P.F. Weller (Eds.).
18. Eschli B., Quirin K., Wepf A., Weber J., Zinkernagel R., Hengartner H. Identification of an N-terminal trimeric coiled-coil core within arenavirus glycoprotein 2 permits assignment to class I viral fusion proteins. J. Virol. 2006, 80:5897-5907.
19. Fisher-Hoch S.P., McCormick J.B. Lassa fever vaccine. Expert Rev. Vaccines 2004, 3:189-197.
20. Fisher-Hoch S.P., Tomori O., Nasidi A., Perez-Oronoz G.I., Fakile Y., Hutwagner L., McCormick J.B. Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. BMJ 1995, 311:857-859.
21. Frame J.D. Clinical features of Lassa fever in Liberia. Rev. Infect. Dis. 1989, 11(Suppl. 4):S783-789.
22. Frame J.D., Baldwin J.M., Gocke D.J., Troup J.M. Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings. Am. J. Trop. Med. Hyg. 1970, 19:670-676.
23. Fuster D., Huertas J.A., Gómez G., Solà R., González García J., Vilaró J., Pedrol E., Force L., Tor J., Sirera G., Videla S., Planas R., Clotet B., Tural C. Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-α2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy. Antivir. Ther. 2005, 10:841-847. for the PEG-TOX Research Group.
24. Gallaher W.R., DiSimone C., Buchmeier M.J. The viral transmembrane superfamily: possible divergence of Arenavirus and Filovirus glycoproteins from a common RNA virus ancestor. BMC Microbiol. 2001, 1:1.
25. Geisbert T.W., Jones S., Fritz E.A., Shurtleff A.C., Geisbert J.B., Liebscher R., Grolla A., Ströher U., Fernando L., Daddario K.M., Guttieri M.C., Mothé B.R., Larsen T., Hensley L.E., Jahrling P.B., Feldmann H. Development of a new vaccine for the prevention of Lassa fever. PLoS Med. 2005, 2:e183.
26. Gowen B.B., Holbrook M.R. Animal models of highly pathogenic RNA viral infections: hemorrhagic fever viruses. Antiviral Res. 2008, 78:79-90.
27. Gowen B.B., Wong M.-H., Jung K.-H., Sanders A.B., Mendenhall M., Bailey K.W., Furuta Y., Sidwell R.W. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob. Agents Chemother. 2007, 51:3168-3176.
28. Gowen B.B., Smee D.F., Wong M.-H., Hall J.O., Jung K.-H., Bailey K.W., Stevens J.R., Furuta Y., Morrey J.D. Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLoS One 2008, 3:e3725.
29. Hooper J.W., Kamrud K.I., Elgh F., Custer D., Schmaljohn C.S. DNA vaccination with hantavirus M segment elicits neutralizing antibodies and protects against Seoul virus infection. Virology 1999, 255:269-278.
30. Huggins J.W. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev. Infect. Dis. 1989, 11(Suppl. 4):S750-761.
31. Imported Lassa fever-New Jersey, 2004. MMWR Morb. Mortal. Wkly Rep. 53, 894-897.
32. Isaäcson M. Viral hemorrhagic fever hazards for travelers in Africa. Clin. Infect. Dis. 2001, 33:1707-1712.
33. Jahrling P.B. Protection of Lassa virus-infected guinea pigs with Lassa-immune plasma of guinea pig, primate, and human origin. J. Med. Virol. 1983, 12:93-102.
34. Jahrling P.B., Peters C.J. Serology and virulence diversity among Old-World arenaviruses, and the relevance to vaccine development. Med. Microbiol. Immunol. 1986, 175:165-167.
35. Jahrling P.B., Hesse R.A., Eddy G.A., Johnson K.M., Callis R.T., Stephen E.L. Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin. J. Infect. Dis. 1980, 141:580-589.
36. Jahrling P.B., Smith S., Hesse R.A., Rhoderick J.B. Pathogenesis of Lassa virus infection in guinea pigs. Infect. Immun. 1982, 37:771-778.
37. Jahrling P.B., Peters C.J., Stephen E.L. Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys. J. Infect. Dis. 1984, 149:420-427.
38. Johnson K.M., McCormick J.B., Webb P.A., Smith E.S., Elliott L.H., King I.J. Clinical virology of Lassa fever in hospitalized patients. J. Infect. Dis. 1987, 155:456-464.
39. Kenyon R.H., Canonico P.G., Green D.E., Peters C.J. Effect of ribavirin and tributylribavirin on Argentine hemorrhagic fever (Junin virus) in guinea pigs. Antimicrob. Agents Chemother. 1986, 29:521-523.
40. Kitching A., Addiman S., Cathcart S., Bischop L., Krahé D., Nicholas M., Coakley J., Lloyd G., Brooks T., Morgan D., Turbitt D. A fatal case of Lassa fever in London, January 2009. Euro Surveill. 2009, 14(6). pii=19117.
41. Kumar K.S., Russo M.W., Borczuk A.C., Brown M., Esposito S.P., Lobritto S.J., Jacobson I.M., Brown R.S. Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am. J. Gastroenterol. 2002, 97:2432-2440.
42. Larson R.A., Dai D., Hosack V.T., Tan Y., Bolken T.C., Hruby D.E., Amberg S.M. Identification of a broad-spectrum arenavirus entry inhibitor. J. Virol. 2008, 82:10768-10775.
43. Lassa Fever Imported to England, 2000a. Commun. Dis. Rep. CDR Wkly 10, 99.
44. Lassa Fever, 2000b. Case Imported to Germany. Wkly Epidemiol. Rec. 75, 17-18.
45. Lassa Fever, 2000c. Imported Case, Netherlands. Wkly Epidemiol. Rec. 75, 265.
46. Lee A.M., Rojek J.M., Spiropoulou C.F., Gundersen A.T., Jin W., Shaginian A., York J., Nunberg J.H., Boger D.L., Oldstone M.B.A., Kunz S. Unique small molecule entry inhibitors of hemorrhagic fever arenaviruses. J. Biol. Chem. 2008, 283:18734-18742.
47. Lenz O., ter Meulen J., Klenk H.-D., Seidah N.G., Garten W. The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. Proc. Natl. Acad. Sci. USA 2001, 98:12701-12705.
48. Liao B.S., Byl F.M., Adour K.K. Audiometric comparison of Lassa fever hearing loss and idiopathic sudden hearing loss: evidence for viral cause. Otolaryngol. Head Neck Surg. 1992, 106:226-229.
49. Lippi G., Salvagno G.L., Montagnana M., Brocco G., Guidi G.C. Influence of hemolysis on routine clinical chemistry testing. Clin. Chem. Lab. Med. 2006, 44:311-316.
50. Lucia H.L., Coppenhaver D.H., Baron S. Arenavirus infection in the guinea pig model: antiviral therapy with recombinant interferon-alpha, the immunomodulator CL246,738 and ribavirin. Antiviral Res. 1989, 12:279-292.
51. Lukashevich I.S., Patterson J., Carrion R., Moshkoff D., Ticer A., Zapata J., Brasky K., Geiger R., Hubbard G.B., Bryant J., Salvato M.S. A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J. Virol. 2005, 79:13934-13942.
52. Maeda H., Kawaguchi H., Sato K., Satake S., Izumi H., Miyajima H. Spontaneous multiple focal to massive hepatic necrosis in guinea pigs. J. Toxicol. Pathol. 2000, 13:207-212.
53. Mahdy M.S., Chiang W., McLaughlin B., Derksen K., Truxton B.H., Neg K. Lassa fever: the first confirmed case imported into Canada. Can. Dis. Wkly Rep. 1989, 15:193-198.
54. McCormick J.B. Clinical, epidemiologic, and therapeutic aspects of Lassa fever. Med. Microbiol. Immunol. 1986, 175:153-155.
55. McCormick J.B. Epidemiology and control of Lassa fever. Curr. Top. Microbiol. Immunol. 1987, 134:69-78.
56. McCormick J.B., King I.J., Webb P.A., Scribner C.L., Craven R.B., Johnson K.M., Elliott L.H., Belmont-Williams R. Lassa fever. Effective therapy with ribavirin. N. Engl. J. Med. 1986, 314:20-26.
57. McCormick J.B., King I.J., Webb P.A., Johnson K.M., O'Sullivan R., Smith E.S., Trippel S., Tong T.C. A case-control study of the clinical diagnosis and course of Lassa fever. J. Infect. Dis. 1987, 155:445-455.
58. McCormick J.B., Webb P.A., Krebs J.W., Johnson K.M., Smith E.S. A prospective study of the epidemiology and ecology of Lassa fever. J. Infect. Dis. 1987, 155:437-444.
59. Mertens P.E., Patton R., Baum J.J., Monath T.P. Clinical presentation of Lassa fever cases during the hospital epidemic at Zorzor, Liberia, March-April 1972. Am. J. Trop. Med. Hyg. 1973, 22:780-784.
60. Mira J.A., López-Cortés L.F., Merino D., Arizcorreta-Yarza A., Rivero A., Collado A., Ríos-Villegas M.J., González-Serrano M., Torres-Tortoso M., Macías J., Valera-Bestard B., Fernández-Fuertes E., Girón-González J.A., Lozano F., Pineda J.A. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients. Antivir. Ther. 2007, 12:1225-1235. Grupo para el Estudio de las Hepatitis Viricas de la Sociedad Andaluza de Enfermedades Infecciosas.
61. Monath T.P., Maher M., Casals J., Kissling R.E., Cacciapuoti A. Lassa fever in the Eastern Province of Sierra Leone, 1970-1972. II. Clinical observations and virological studies on selected hospital cases. Am. J. Trop. Med. Hyg. 1974, 23:1140-1149.
62. Müller S., Günther S. Broad-spectrum antiviral activity of small interfering RNA targeting the conserved RNA termini of Lassa virus. Antimicrob. Agents Chemother. 2007, 51:2215-2218.
63. Peters C.J., Jahrling P.B., Liu C.T., Kenyon R.H., McKee K.T., Barrera Oro J.G. Experimental studies of arenaviral hemorrhagic fevers. Curr. Top. Microbiol. Immunol. 1987, 134:5-68.
64. Sonntag O. Haemolysis as an interference factor in clinical chemistry. J. Clin. Chem. Clin. Biochem. 1986, 24:127-139.
65. Stephen E.L., Jones D.E., Peters C.J., Eddy G.A., Loizeaux P.S., Jahrling P.B. Ribavirin treatment of toga-, arena- and bunyavirus infections in subhuman primates and other laboratory animal species. Ribavirin: A Broad Spectrum Antiviral Agent 1980, 169-183. Academic Press, New York. R.A. Smith, W. Kirkpatrick (Eds.).
66. Tomori O., Johnson K.M., Kiley M.P., Elliott L.H. Standardization of a plaque assay for Lassa virus. J. Med. Virol. 1987, 22:77-89.
67. Walker D.H., Wulff H., Lange J.V., Murphy F.A. Comparative pathology of Lassa virus infection in monkeys, guinea-pigs, and Mastomys natalensis. Bull. World Health Organ. 1975, 52:523-534.
68. Wright K.E., Spiro R.C., Burns J.W., Buchmeier M.J. Post-translational processing of the glycoproteins of lymphocytic choriomeningitis virus. Virology 1990, 177:175-183.
69. York J., Agnihothram S.S., Romanowski V., Nunberg J.H. Genetic analysis of heptad-repeat regions in the G2 fusion subunit of the Junín arenavirus envelope glycoprotein. Virology 2005, 343:267-274.